Aalborg University professor Søren Nielsen, MD, dr.med. is one of the world's leading scientists in the field of cellular/molecular biology, physiological and pathological studies of aquaporins, sodium channels and transporters with more than 380 articles published. He brings to 2A Pharma also invaluable business knowledge through Action Pharma A/S where he was co-founder and Executive (CEO 2001-2010, COO 2010-2012) and raised EUR 30 million to conduct clinical trials (Phase 2a & 2b) with AP214 – a candidate for acute renal failure – in Europe and the United States. AP214 was acquired in May 2012 by Abbott, Chicago (~ $ 110 million). For his research, he has received several awards, including the Novo Nordisk Prize, the Novo Nordisk Foundation 2009.
E-mail: firstname.lastname@example.orgTelephone: +45 2539 4137
John D. Nieland, PhD, Associate professor, brings broad management experience, an in-depth research background in immunology and an expertise in the development of biopharmaceuticals and coordination and development of clinical trials. He worked as head of immunology and later director of research at Medigene AG, where has was involved in the development of the AAV-HPV vaccine, and held the position of vice president preclinical research at Borean Pharma. John initiated and collaborated on numerous projects, has published more than 30 articles and is the inventor of 15 patents, including several on the AAV vaccine platform. In addition to his scientific experience, John has extensive business experience and is the founder/co-founder of three biotech companies.
E-mail: email@example.comTelephone: +45 2248 2276
Preben Bruun-Nyzell is a finance executive with more than 20 years international experience in finance and finance systems. He was previously Chief Financial Officer of Qatalum in Qatar, an aluminum producer with annual sales of USD 1.5 billion, and has held senior positions with EMAL in Abu Dhabi, Arqaam Capital in Dubai, Accenture and PwC in London and Hoffmann-La Roche AG in Basel, Switzerland. Preben holds a degree in Business Administration from Lancaster University in the UK and Università Bocconi, Milan, Italy. He is a board member of Apoglyx AB.
E-mail: firstname.lastname@example.orgTelephone: +46 760 58 01 08
Jeanette Prangsgaard holds a Bachelor of Industrial Medicine and a Master of Biomedicine from the Laboratory of Immunology at Aalborg University with a master's thesis on dendritic cells as potential target for turning vaccination into a cure for cancer, autoimmune diseases and allergy. Jeanette has wide experience in laboratory techniques such as harvesting and culturing blood cells and stem cells and methods such as flow cytometry, confocal microscopy, PCR, qPCR, NMR, PPL and TGA.
E-mail: email@example.comTelephone: +45 2855 0216